> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-67/
- Published: 2022-03-20T12:00:00.000Z
- Updated: 2026-09-14T17:37:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136848

**OncoImmune** has entered into an exclusive option and license agreement with **Pfizer** for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody, in a deal worth up to $250 million in upfront and potential milestone payments. Under the terms of the agreement, Pfizer plans to evaluate ONC-392 up until a certain agreed-upon time to determine whether it will exercise its option to exclusively license ONC-392 as well as any other OncoImmune anti-CTLA4 antibodies.

**Horizon Discovery Group** has entered into a collaboration with **Fulcrum Therapeutics** that will utilize Horizon’s CRISPR-based screening platform to identify novel targets for regulating gene expression. The program will initially focus on genetic diseases where no effective treatment options currently exist.

**Zimmer Biomet Holdings** has acquired **Clinical Graphics**, an imaging company specializing in 3D range-of-motion simulation technology to inform treatment decisions for common hip conditions requiring early intervention. Zimmer plans to integrate the new imaging platform to enhance its hip preservation portfolio.

**Johnson & Johnson** has announced a definitive agreement to acquire **Abbott Medical Optics** for $4.325 billion in cash. The acquisition will include ophthalmic products in three business segments: cataract surgery, laser refractive surgery and consumer eye health.

**GE** says it will invest $150 million in a new biopharmaceutical manufacturing campus in Cork, Ireland. GE BioPark Cork will feature Europe’s first KUBio, prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, that will serve as a focal point for further investment in next-generation biopharmaceutical manufacturing in Ireland.